脂质药物偶联（LDC）纳米颗粒作为自淋巴靶向载体制剂口服递送甲氨蝶呤。
Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate.
机构信息
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar 470003, M.P., India.
出版信息
J Biomed Nanotechnol. 2011 Feb;7(1):130-1. doi: 10.1166/jbn.2011.1235.
PMID:21485837
Abstract
The objective of the study was to develop lipid drug conjugate nanoparticles (LDC-NPs) of anticancer drug methotrexate (MTX) for oral delivery that faces problems of low and variable bioavailability. The MTX loaded LDC-NPs significantly enhanced bioavailability and reduced MTX associated gastrointestinal toxicity even in higher doses recommended for anticancer therapy.
摘要
本研究旨在开发载有抗癌药物甲氨蝶呤 (MTX) 的脂质药物偶联纳米粒 (LDC-NPs)，用于口服递送，但存在生物利用度低且变异性大的问题。载有 MTX 的 LDC-NPs 可显著提高生物利用度，并降低 MTX 相关的胃肠道毒性，即使在推荐用于癌症治疗的较高剂量下也是如此。
Zotero 插件